$BSX

BOSTON SCIENTIFIC CORP

Boston Scientific develops, manufactures and markets medical devices used in interventional medical specialties. Its products help physicians and other health care professionals diagnose and treat diseases and conditions, often through less-invasive procedures. The company markets to hospitals, clinics, outpatient facilities and medical offices in 127 countries worldwide, using direct sales organizations as well as distributors and dealers. Boston Scientific has two reportable segments: MedSurg and Cardiovascular. MedSurg includes Endoscopy, Urology and Neuromodulation products, such as gastrointestinal scopes, devices for urinary and pelvic conditions, and systems for chronic pain and movement disorders. Cardiovascular includes technologies for coronary and vascular disease, stroke-risk reduction, heart rhythm disorders and cancer treatment, including WATCHMAN closure devices, FARAPULSE ablation systems, cardiac implants and embolization products. Boston Scientific makes money by selling its medical devices and related solutions to health care providers and buying groups. It is headquartered in Marlborough, Massachusetts.

0
10
7

No SEC Form 4 filings for $BSX in the last 30 days.

See all $BSX insider activity →
Med

BSX's Weak Solvency and Cash Conversion Raise Financing Risk

Boston Scientific (BSX) reported $609M in cash, $11.95B in debt, and Q3 free cash flow of $867M. Adjusted gross margin fell 300bps YoY to 68% due to a cybersecurity incident. BSX lowered its full-year free cash flow outlook to $3.6B. The company faces margin pressure, pricing pressure in China, and acquisition-related obligations. BSX shares have declined 56% YoY, trading at a 12-month forward P/S of 3.00X. Analysts have reduced BSX's 2026 earnings estimate by 2.2% over the past 30 days.

Why You Should Think About Boston Scientific Differently Now

Boston Scientific (BSX) stock is down 57.1% over the past year, trading at 18.1x earnings. Management now focuses on 75% of the business growing steadily, as WATCHMAN and EP units weigh on growth. Fiscal Q3 2026 saw organic sales rise 1.5%, with interventional cardiology up 19% but urology down 3% due to a cyber incident.

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.

BSX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 17 news stories mentioning BSX (BOSTON SCIENTIFIC CORP). Coverage has skewed bearish: 0 bullish, 10 neutral, and 7 bearish.

Recent BSX coverage spans financial news, market movers and mergers & acquisitions.

What's driving BSX

  • Guidance cut and cash-conversion concerns likely increase financing-risk and valuation pressure, especially with ongoing buyback and acquisition commitments.

    tradingview.com · Nov 19, 2026

  • Boston Scientific faces pressure from slower organic growth and a recent cyber outage.

    finance.yahoo.com · Nov 19, 2026

  • No actionable BSX-specific catalyst is disclosed in the text.

    baystreet.ca · Nov 19, 2026

  • Financing terms add downside risk if the Penumbra deal fails to close, because noteholders must be repaid early at 101% plus accrued interest.

    quantisnow.com · Nov 19, 2026

  • Board-approved executive compensation framework and a lead independent director transition are unlikely to change near-term fundamentals, but can affect governance optics and incentive alignment.

    tipranks.com · Nov 17, 2026

AlphAI scores every news story that mentions BSX with an AI model for sentiment and relevance, and aggregates insider trades from BOSTON SCIENTIFIC CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BSX

Score

BSX's Weak Solvency and Cash Conversion Raise Financing Risk

Boston Scientific (BSX) reported $609M in cash, $11.95B in debt, and Q3 free cash flow of $867M. Adjusted gross margin fell 300bps YoY to 68% due to a cybersecurity incident. BSX lowered its full-year free cash flow outlook to $3.6B. The company faces margin pressure, pricing pressure in China, and acquisition-related obligations. BSX shares have declined 56% YoY, trading at a 12-month forward P/S of 3.00X. Analysts have reduced BSX's 2026 earnings estimate by 2.2% over the past 30 days.

Why You Should Think About Boston Scientific Differently Now

Boston Scientific (BSX) stock is down 57.1% over the past year, trading at 18.1x earnings. Management now focuses on 75% of the business growing steadily, as WATCHMAN and EP units weigh on growth. Fiscal Q3 2026 saw organic sales rise 1.5%, with interventional cardiology up 19% but urology down 3% due to a cyber incident.

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.

$BSXLowExec change· appointed

BOSTON SCIENTIFIC CORP (BSX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

BOSTON SCIENTIFIC CORP (BSX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (i) 2027 Annual Bonus Plan On November 17, 2026, upon the recommendation of the Executive Compensation and Human Resources

Is Boston Scientific Still The Business You Bought?

Boston Scientific (BSX) reported a 57.4% stock decline over 12 months to November 13, 2026, despite improved operating margins. The company increased capital spending, leading to lower cash reserves. Revenue growth slowed to 1.4% in Q3 2026, partly due to a cyberattack and market share losses in key franchises. Management expects 2027 to be a low point and aims for recovery in 2028.

Watchman Nears $2 Billion Amid Trial Questions

Boston Scientific's Watchman device nears $2 billion in 2025 sales, with 800,000 implants worldwide. Recent trials show mixed results compared to blood thinners, with some cases worse. The company continues marketing despite criticism from experts like Dr. Gregory Marcus, who question its broad effectiveness. Watchman sales grew 30% from 2024, contributing to Boston Scientific's $20 billion net sales in 2025.

Coherent and Boston Scientific have been highlighted as Zacks Bull and Bear of the Day

Zacks Equity Research named Coherent (COHR) as Bull of the Day, citing strong Q1 results with 50% revenue growth to $2.37B, 80% earnings growth, and raised long-term margin targets. Boston Scientific (BSX) was named Bear of the Day due to lowered guidance and falling shares. CoreWeave (CRWV) was also analyzed. COHR's Q2 outlook is $2.55B-$2.75B revenue, $2.28-$2.48 EPS. Analysts raised FY2027 EPS estimates to $10.25 and FY2028 to $15.38. COHR's CEO bought 5,000 shares at $199.48 each.

Boston Scientific Bets on WATCHMAN Growth Despite Market Slowdown

Boston Scientific (BSX) reports slowing demand for its WATCHMAN device, expecting low-single-digit sales decline in Q3 2026. The company invests in education and trials to expand adoption. Abbott (ABT) sees growth in electrophysiology, while Edwards Lifesciences (EW) reports 3% growth in surgical structural heart sales. BSX stock is down 57% year-over-year, trading at a 3.15X forward P/S ratio.

Related tickers